Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 16, 2026 in Doximity, Inc. Lawsuit - DOCS
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 16, 2026 in Doximity, Inc. Lawsuit - DOCS
PR Newswire
NEW YORK, Sept. 23, 2026
Doximity reported "record engagement" using metrics of its own design, yet the securities action contends its disclosures omitted the market share erosion and light-engagement advertising methods that were already reshaping DOCS revenue.
NEW YORK, Sept. 23, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Doximity, Inc. (NYSE: DOCS) that a securities class action has been filed on behalf of shareholders who purchased common stock between August 8, 2024 and May 13, 2026. Find out if you might qualify for recovery. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
DOCS holders absorbed three separate declines totaling $19.26 per share: $8.29 (13%) on November 7, 2025, $5.59 (17%) on February 6, 2026, and $5.38 (23%) on May 14, 2026, the last carrying the stock from $23.39 to $18.01. Motions for lead plaintiff appointment must be filed by November 16, 2026.
What the Company Disclosed
Doximity measured itself largely with figures of its own construction. SEC filings and quarterly calls reported "record engagement," more than 1 million quarterly active prescribers, and double-digit growth in "articles read or tapped," while revenue was billed through a proprietary "cost-per-target" structure under which customers subscribe to modules to reach a set number of members each month. Company marketing materials accessible throughout the class period stated that Doximity does not "bombard physicians with ads and messages in hopes of getting lucky."
What Plaintiffs Allege Was Missing
The complaint challenges whether those company-defined figures told shareholders anything about the commercial trends that actually governed growth.
Disclosure Gaps Alleged
- Engagement counts were allegedly reported without the corresponding revenue contribution, overstating the Newsfeed's impact on sales growth
- No disclosure that older advertising formats were allegedly losing share while programmatic and social formats gained, a dynamic Evercore described after February 5, 2026
- Alleged reliance on banner ads and email newsletters, methods the Company's own materials disclaimed
- Net revenue retention, later characterized by RBC Capital Markets as stalled in an "increasingly competitive market," allegedly not framed as a deteriorating indicator
- A shift in which pharmaceutical customers deployed lower percentages of their budgets upfront, a pattern discussed only after fiscal 2026 guidance was reduced
Why Generic Warnings May Not Protect
Disclosure language indicated confidence in competitive position and engagement quality. The action contends that boilerplate cautionary wording did not cure the omission of specific, already-developing pressures on pharmaceutical ad budgets, and that investors bought at prices reflecting the favorable figures rather than the underlying trend.
"Generic risk factor language cannot substitute for disclosing specific, known problems that are already affecting a company's operations. Here the action asserts Doximity continued reporting record engagement metrics while its share of pharmaceutical advertising spend was allegedly eroding." -- Joseph E. Levi, Esq.
Submit your information now or call (212) 363-7500.
Levi & Korsinsky, LLP is a nationally recognized shareholder rights firm. Over the past 20 years, the firm has secured hundreds of millions of dollars for aggrieved shareholders. Ranked in ISS Top 50 for seven consecutive years.
Frequently Asked Questions About the DOCS Lawsuit
Q: When did Doximity allegedly mislead investors? A: The Class Period runs from August 8, 2024 to May 13, 2026. The complaint alleges that multiple corrective disclosures events revealed information that caused significant stock declines.
Q: What court was the DOCS class action filed in? A: The case was filed in the United States District Court for the Northern District of California, governed by the Private Securities Litigation Reform Act of 1995.
Q: Who are the defendants named in the DOCS lawsuit? A: The complaint names Doximity, Inc. and a set of individual defendants who held senior positions at the company for all or part of the Class Period, including co-founder, CEO, and Chairman Jeffrey Tangney, CFO Anna Bryson, co-founder and Chief Strategy Officer Nate Gross, and VP of Investor Relations & Revenue Operations, Perry Gold.
Q: What do DOCS investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible as an absent class member.
Q: What happens after I contact Levi & Korsinsky? A: An attorney will review your trading history at no cost and provide an initial assessment of your potential eligibility.
Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.
Q: Can I join a different law firm's lawsuit instead? A: Yes. Investors may choose which law firm to contact. Multiple firms often file competing complaints. The court may consolidate related cases and appoint a single lead counsel.
Q: What if I live outside the United States? A: U.S. securities class actions generally cover purchases on U.S. exchanges regardless of the investor's country of residence.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
SOURCE Levi & Korsinsky, LLP
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States